Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk

We read with great interest the paper by Lorberbaum et al. (1) recently published in the Journal, in which evidence was provided that ceftriaxone plus lansoprazole combination therapy (CFX+LSZ) was unexpectedly associated with an increased risk of acquired long QT syndrome (aLQTS); thus, it is also theoretically associated with Torsades de Pointes (TdP) and sudden cardiac death. We report on 2 clinical observations that possibly further support these findings.